$BIXT announced that it has retained Juan Carlos Lopez-Talavera, MD, PhD to join Bioxytran’s Scientific Advisory Board to manage the company’s FDA regulatory application process for Bioxytran’s flagship drug, BXT-25.
https://finance.yahoo.com/news/bioxytran-inc-...26145.html